期刊文献+

甘精胰岛素用于Ⅱ型糖尿病患者术后血糖控制的探讨 被引量:2

Post-operative Glycemic Control by Insulin Glargine in Type 2 Diabetic Patient
原文传递
导出
摘要 目的:探讨甘精胰岛素用于II型糖尿病患者手术后血糖控制的可行性。方法:选择51例接受外科手术后的II型糖尿病患者,分为甘精胰岛素治疗组(LAN组)16例,常规生物合成人胰岛素治疗组(MSII组)19例,胰岛素泵治疗组(CSII组)16例。LAN组患者术后使用甘精胰岛素,视空腹血糖变化情况调整其剂量,患者如进食则于餐前给予短效胰岛素。MSII组术后用静脉胰岛素输注,患者进食后可逐渐采用传统胰岛素强化治疗方案(R+R+R+NPH)。CSII组每天24 h持续泵入短效胰岛素,禁食期只给予基础量,进食后给予基础和餐时量。观察各组患者治疗前后血糖变化、胰岛素用量、低血糖发生率及术后并发症发生率,酮症发生率。结果:各组治疗后血糖均明显低于治疗前,LAN组治疗后血糖低于MSII组,与CSII组无明显差异;LAN组低血糖发生率低于MSII组,而与CSII比较无显著性差异。结论:II型糖尿病患者术后禁食或进食不规律阶段,使用常规胰岛素治疗,血糖波动较大且患者依从性差;甘精胰岛素在糖尿病患者手术后降糖效果显著,能迅速、平稳控制血糖且患者依从性好,是一种安全、有效且患者易接受的用于II型糖尿病患者术后治疗的药物。 Objective:To determine the feasibility of postoperative glycemic control with insulin glargine in type 2 diabetes mellitus(T2DM).Methdos:51 patients with T2DM receiving surgical intervention.They were divided into three groups: insulin glargine(LAN group,n=16),multiple subcutaneous insulin injection(MSII group,n=19) and insulin pump(CSII group,n=16).LAN group of patients using insulin glargine,as fasting blood glucose changes in their dose adjustments,giving short-acting insulin when eating.MSII group using...
作者 乔媛 王养维
出处 《微量元素与健康研究》 CAS 2009年第1期11-13,共3页 Studies of Trace Elements and Health
关键词 Ⅱ型糖尿病 甘精胰岛素 术后 T2DM insulin glargine postoperation
  • 相关文献

参考文献9

  • 1Levien TL,Baker DE,White JR Jr,Campbell RK.Insulinglargine:a new basal insulin[].Annals of Pharmacotherapy.2002
  • 2Hoogwerf BJ.Perioperative management of diabetes mellitus:How should we act on the limited evidence[].Cleveland Clinic Journal of Medicine.2006
  • 3Hoogwerf BJ.Postoperative management of the diabetic patient[].The Medical Clinics of North America.2001
  • 4Marks JB.Perioperative management of diabetes[].American Family Physician.2003
  • 5Bergman SA.Perioperative management of the diabetic patient[].Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2007
  • 6Edelman SV.Pumb and type2diabetes[].Diabetes Forecast.2002
  • 7Weissberg-Benchell,J.,Antisdel-Lomaglio,J.,Seshadri,R.Insulin pump therapy: a meta-analysis[].Diabetes Care.2003
  • 8Lepore M,Pampanelli S,Fanelli C,et al.Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro[].Diabetes.2000
  • 9R. Keith Campbell BPharm John R. White PharmD Terri Levien PharmD and Danial Baker PharmD.Insulin glargine[].Clinical Therapeutics.2001

同被引文献9

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部